BR112015025398A2 - inibidores de metástase - Google Patents

inibidores de metástase

Info

Publication number
BR112015025398A2
BR112015025398A2 BR112015025398A BR112015025398A BR112015025398A2 BR 112015025398 A2 BR112015025398 A2 BR 112015025398A2 BR 112015025398 A BR112015025398 A BR 112015025398A BR 112015025398 A BR112015025398 A BR 112015025398A BR 112015025398 A2 BR112015025398 A2 BR 112015025398A2
Authority
BR
Brazil
Prior art keywords
metastasis inhibitors
methods
inhibiting
cancer
metastasis
Prior art date
Application number
BR112015025398A
Other languages
English (en)
Inventor
Parikh Indu
B Adler Kenneth
Original Assignee
Biomarck Pharmaceuticals Ltd
Univ North Carolina State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarck Pharmaceuticals Ltd, Univ North Carolina State filed Critical Biomarck Pharmaceuticals Ltd
Publication of BR112015025398A2 publication Critical patent/BR112015025398A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Abstract

resumo inibidores de metástase a presente invenção refere-se a métodos e compostos para o tratamento ou prevenção do câncer. os métodos e composições proporcionados incluem incluindo inibir ou suprimir o desenvolvimento, manutenção, e proliferação de câncers, incluindo o bloqueio ou inibição de metástases de células de câncer.
BR112015025398A 2013-04-05 2014-04-07 inibidores de metástase BR112015025398A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361808966P 2013-04-05 2013-04-05
PCT/US2014/033206 WO2014165853A1 (en) 2013-04-05 2014-04-07 Inhibitors of metastasis

Publications (1)

Publication Number Publication Date
BR112015025398A2 true BR112015025398A2 (pt) 2017-10-10

Family

ID=51654619

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015025398A BR112015025398A2 (pt) 2013-04-05 2014-04-07 inibidores de metástase

Country Status (20)

Country Link
US (4) US9408886B2 (pt)
EP (1) EP2981279B1 (pt)
JP (1) JP6449849B2 (pt)
KR (1) KR102191695B1 (pt)
CN (1) CN105517562B (pt)
AU (1) AU2014247979B2 (pt)
BR (1) BR112015025398A2 (pt)
CA (1) CA2908832C (pt)
DK (1) DK2981279T3 (pt)
ES (1) ES2714863T3 (pt)
HK (1) HK1221159A1 (pt)
HU (1) HUE043971T2 (pt)
IL (1) IL241937B (pt)
MX (1) MX363077B (pt)
PL (1) PL2981279T3 (pt)
PT (1) PT2981279T (pt)
RU (1) RU2681213C2 (pt)
SG (2) SG10201708125PA (pt)
WO (1) WO2014165853A1 (pt)
ZA (1) ZA201508010B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014247979B2 (en) 2013-04-05 2018-06-28 Biomarck Pharmaceuticals, Ltd. Inhibitors of metastasis
CN108686220A (zh) * 2018-07-13 2018-10-23 刘慧荣 一种针对甲状腺癌的抗肿瘤剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
AU2002322475B2 (en) 2001-06-26 2008-02-21 North Carolina State University Blocking peptide for inflammatory cell secretion
US20050042202A1 (en) * 2001-10-05 2005-02-24 Weiner David B. Compositions for and methods of treating and preventing sirs/sepsis
DE60308251T2 (de) 2002-04-17 2007-08-30 Canon K.K. Vorrichtung zur Bereitstellung von öffentlichen Schlüsselzertifikaten
MX2007008744A (es) 2005-01-20 2008-03-10 Biomarck Pharmaceuticals Ltd Inhibidores de hipersecrecion de mucina con base en la estructura de mans ymetodos de uso.
WO2006086681A2 (en) 2005-02-09 2006-08-17 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting smooth muscle cell migration and proliferation
CA2658949C (en) * 2006-07-26 2014-04-22 Biomarck Phamaceuticals, Ltd. Inhibition of marcks-mediated degranulation by marcks n-terminal pepetides in treating inflammation
JP2010521135A (ja) 2006-10-06 2010-06-24 セルタクシス，インコーポレイテッド 細胞の化学忌避
KR20090086415A (ko) 2006-10-27 2009-08-12 조지 매이슨 인털렉춸 프로퍼티즈, 인코퍼레이티드 전이성 결장직장 암에 대한 검정
WO2009062128A2 (en) 2007-11-08 2009-05-14 Indiana University Research And Technology Corporation Combination drug therapy for the treatment of cancer
EP2105511A1 (en) * 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
US9073974B2 (en) * 2009-12-21 2015-07-07 The Regents Of The University Of California RGD-containing cyclic peptides
EP3351641A1 (en) * 2011-04-08 2018-07-25 Tufts Medical Center, Inc. Pepducin design and use
AU2014247979B2 (en) * 2013-04-05 2018-06-28 Biomarck Pharmaceuticals, Ltd. Inhibitors of metastasis

Also Published As

Publication number Publication date
MX363077B (es) 2019-03-07
US20210130403A1 (en) 2021-05-06
CA2908832A1 (en) 2014-10-09
US10683328B2 (en) 2020-06-16
EP2981279A4 (en) 2016-11-09
CA2908832C (en) 2023-01-24
PL2981279T3 (pl) 2019-09-30
HK1221159A1 (zh) 2017-05-26
US10011636B2 (en) 2018-07-03
RU2015146997A3 (pt) 2018-03-13
IL241937B (en) 2019-03-31
ES2714863T3 (es) 2019-05-30
AU2014247979A1 (en) 2015-10-29
SG10201708125PA (en) 2017-11-29
US20190119320A1 (en) 2019-04-25
CN105517562B (zh) 2018-12-28
CN105517562A (zh) 2016-04-20
DK2981279T3 (en) 2019-03-25
WO2014165853A1 (en) 2014-10-09
EP2981279B1 (en) 2018-12-19
AU2014247979B2 (en) 2018-06-28
KR20150140736A (ko) 2015-12-16
PT2981279T (pt) 2019-03-14
NZ712955A (en) 2021-03-26
SG11201508249WA (en) 2015-11-27
MX2015014036A (es) 2016-02-25
US20170121369A1 (en) 2017-05-04
RU2015146997A (ru) 2017-05-15
ZA201508010B (en) 2017-01-25
RU2681213C2 (ru) 2019-03-05
EP2981279A1 (en) 2016-02-10
US9408886B2 (en) 2016-08-09
HUE043971T2 (hu) 2019-09-30
JP6449849B2 (ja) 2019-01-09
KR102191695B1 (ko) 2020-12-16
US11466054B2 (en) 2022-10-11
US20140302057A1 (en) 2014-10-09
JP2016516756A (ja) 2016-06-09

Similar Documents

Publication Publication Date Title
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
EA201891057A1 (ru) Композиции и способы для ингибирования активности аргиназы
BR112017023821A2 (pt) moduladores de k-ras
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
PH12017500293A1 (en) Boronic acid derivatives
BR112015032062A2 (pt) aduto de aceitador de michael contendo enxofre, composição, aduto de aceitador de michael contendo enxofre terminado por hidroxila e aduto contendo enxofre terminado por amina
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
MX2017004043A (es) Derivados de acido boronico.
MX2017004037A (es) Derivados de acido boronico.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX370336B (es) Derivados de acido boronico.
BR112017008799A2 (pt) composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
EA201790189A1 (ru) Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
EA201590744A1 (ru) Лечение рака tor киназными ингибиторами
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
HRP20182041T1 (hr) Pripravci oksprenolola za liječenje raka
EP3035924A4 (en) Hdac8 inhibitors for treating cancer
BR112019004481A2 (pt) aptâmeros específicos de pd-1
MX2015013021A (es) 5-bromo-indirrubinas.
EP2986120A4 (en) METHYLTRANSFERASE HEMMER FOR THE TREATMENT OF CANCER

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements